Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study
In this long-term post-hoc update of the TIVO-3 trial, we show that in CPI-resistant mRCC, the PFS benefit of tivozanib over sorafenib is accompanied with improved OS data, although not statistically significant, and durable responses.
Authors
- Camillo Porta (ORCID: https://orcid.org/0000-0003-2412-1563)
- Miguel Zugman (ORCID: https://orcid.org/0000-0002-2181-8405)
- Sumanta Kumar Pal (ORCID: https://orcid.org/0000-0002-1712-0848)
- Bernard Escudier (ORCID: https://orcid.org/0000-0002-4626-0479)
- Elena Verzoni (ORCID: https://orcid.org/0000-0001-9756-6112)
- David H. McDermott (ORCID: https://orcid.org/0000-0001-6978-0867)
- Thomas E. Hutson (ORCID: https://orcid.org/0000-0002-4529-4212)
- Michael B. Atkins
- Brian Rini
Institutions
- Texas Tech University (US)
- Beth Israel Deaconess Medical Center (US)
- Georgetown University (US)
- Vanderbilt University (US)
- Georgetown University Medical Center (US)
- Institut Gustave Roussy (FR)
- University Medical Center (US)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- City of Hope (US)
- Dana-Farber/Harvard Cancer Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University of Bari Aldo Moro (IT)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1093/oncolo/oyae369
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- European Society for Medical Oncology